Cue Biopharma, Inc. Quick Ratio
The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.
- Cue Biopharma, Inc. quick ratio for the quarter ending 2026-06-30 was 1.07, a 26.27% decline year-over-year.
- Cue Biopharma, Inc. quick ratio for the quarter ending 2026-03-31 was 2.94, a 246.87% increase year-over-year.
- Cue Biopharma, Inc. quick ratio for the quarter ending 2025-12-31 was 2.42, a 41.66% increase year-over-year.
- Cue Biopharma, Inc. quick ratio for the quarter ending 2025-09-30 was 0.78, a 63.25% decline year-over-year.
- Cue Biopharma, Inc. quick ratio for fiscal 2025 was 2.42, a 41.66% increase from fiscal 2024.
- Cue Biopharma, Inc. quick ratio for fiscal 2024 was 1.71, a 41.84% decline from fiscal 2023.
- Cue Biopharma, Inc. quick ratio for fiscal 2023 was 2.94, a 34.30% decline from fiscal 2022.
- Cue Biopharma, Inc. quick ratio for fiscal 2022 was 4.47, a 15.25% decline from fiscal 2021.
- Available history
- 2017-12-31 to 2026-06-30
- Data captured
Historical Quick Ratio
Annual Quick Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |